Publications by authors named "Nikos Lyris"
Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease that causes pain and fatigue, reduces physical function, and negatively impacts health-related quality of life (HRQoL). In the phase III BE OPTIMAL and BE COMPLETE studies, bimekizumab demonstrated clinical efficacy and meaningful improvements in patient-reported outcome (PRO) measures in biologic disease-modifying antirheumatic drug (bDMARD)-naïve patients, and those who had prior inadequate response/intolerance to tumor necrosis factor inhibitors (TNFi-IR).
Objectives: To examine the association between achieving increasingly stringent clinical disease control criteria and improvements in PRO measures in patients with active PsA receiving bimekizumab.
Article Synopsis
- The study assessed the effectiveness of bimekizumab versus risankizumab in treating psoriatic arthritis (PsA) over 52 weeks, focusing on patients either new to biologic treatment (bDMARD naïve) or those who had previously not responded to tumor necrosis factor inhibitors (TNFi-IR).
- Data from relevant clinical trials were matched and analyzed using statistical methods to account for differences between the trial populations, ensuring a fair comparison of outcomes like the American College of Rheumatology (ACR) response criteria and minimal disease activity (MDA).
- Results indicated that bimekizumab showed a significantly higher likelihood of response at Wk52 compared to ris
Article Synopsis
- A matching-adjusted indirect comparison (MAIC) was performed to evaluate the efficacy of bimekizumab versus ustekinumab in treating psoriatic arthritis patients, focusing on those who are naïve to biologic drugs or had previously inadequate responses to tumor necrosis factor inhibitors.
- Individual patient data from two bimekizumab trials were matched with summary data from multiple ustekinumab trials, using propensity scores to balance baseline characteristics.
- Results showed that bimekizumab had significantly higher response rates for various American College of Rheumatology (ACR) criteria at 52 weeks compared to ustekinumab in both bDMARD naïve and TNFi-IR patients.
Article Synopsis
- A previous study found that bimekizumab, an inhibitor targeting both IL-17A and IL-17F, is effective for treating radiographic axial spondyloarthritis compared to other treatments like secukinumab and ixekizumab over 16 weeks.
- This analysis used individual patient data from the BE MOBILE 2 trial and compared it with pooled data from multiple trials involving secukinumab and ixekizumab by adjusting for factors like age and baseline disease severity.
- Results indicated that after 52 weeks, patients on bimekizumab showed a greater chance of improvement in key efficacy measures compared to secukinumab, while differences with ixekizumab were mostly not significant, highlighting
Article Synopsis
- This study evaluates the cost-effectiveness of bimekizumab (BKZ) for treating axial spondyloarthritis (axSpA) compared to other IL-17 inhibitors like secukinumab (SEC) and ixekizumab (IXE) from the perspective of NHS Scotland.
- A decision tree and lifetime Markov model were used to analyze treatment pathways, focusing on the cost and quality of life outcomes measured in quality-adjusted life-years (QALYs) using data on efficacy, costs, and patient transitions based on disease activity.
- The findings indicated that BKZ had an incremental cost-effectiveness ratio of £24,801/QALY compared to SEC, with similar costs and health benefits when
Article Synopsis
- - The study utilized matching-adjusted indirect comparisons (MAIC) to evaluate the effectiveness of bimekizumab versus guselkumab in treating patients with psoriatic arthritis who had not previously received biologic therapy or had inadequate responses to TNF inhibitors.
- - Data were collected from systematic literature reviews and multiple clinical trials, allowing for comparisons of treatment outcomes based on individual patient data and summary data from various studies.
- - Results showed that bimekizumab was significantly more effective than guselkumab in achieving higher rates of improvement in American College of Rheumatology scores and minimal disease activity in both treatment-naïve and TNFi-resistant patient groups.
Article Synopsis
- The study used Matching-Adjusted Indirect Comparisons (MAICs) to evaluate the effectiveness of bimekizumab versus secukinumab in treating psoriatic arthritis after 52 weeks of treatment in patients who had either never received biologics or had inadequate responses to TNF inhibitors.
- Patients from two bimekizumab trials had their data matched to aggregate data from another trial involving secukinumab to ensure fair comparisons based on similar baseline characteristics.
- The results indicated that bimekizumab showed a significantly higher likelihood of achieving major improvement scores (ACR20/50/70) and minimal disease activity compared to both doses of secukinumab in both